La vendita allo scoperto per Icon dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Icon. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Icon (NASDAQ:ICLR) Azioni, Report sulle vendite allo scoperto

Icon

Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.

Icon PLC

WIIM

ICLR

Icon shares are trading higher. Truist Securities maintained a Buy rating on the stock.

Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) has outperformed the market over the past 15 years by 3.83% on an annualized basis producing an average annual return of 15.94%. Currently, Icon has a market capitalization of $18.20 billion. 
Buying $1000 In ICLR: If an investor had bought $1000 of ICLR stock 15 years ago, it would be worth $9,139.97 today based on a price of $220.47 for ICLR at the time of writing.
<h3>Icon's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730125812_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$1000 Invested In This Stock 15 Years Ago Would Be Worth $9,100 Today

Truist Securities analyst Jailendra Singh maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Buy and lowers the price target from $363 to $295.

Price Target

Analyst Ratings

Truist Securities Maintains Buy on Icon, Lowers Price Target to $295

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>ICON plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) shares plummeted 25.95% after the company reported <a href="https://www.benzinga.com//node/41500867" target="_blank" rel="noreferrer noopener">worse-than-expected results</a>. Several analysts also cut the <a href="https://www.benzinga.com/quote/iclr/analyst-ratings" target="_blank" rel="noreferrer noopener">price target on the stock</a>.</li>
<li>Genuine Parts Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPC#NYSE">GPC</a>) stock tumbled 20.21% after it reported mixed third-quarter results and cut its <a href="https://www.benzinga.com//node/41455012" target="_blank" rel="noreferrer noopener">FY24 EPS below estimates</a>. Multiple analysts cut the <a href="https://www.benzinga.com/quote/gpc/analyst-ratings" target="_blank" rel="noreferrer noopener">price target on the stock</a>.</li>
<li>Newmont Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) shares dipped 15.97% after the company reported <a href="https://www.benzinga.com//node/41503948" target="_blank" rel="noreferrer noopener">third-quarter financial results</a>. Analysts trimmed the <a href="https://www.benzinga.com/quote/nem/analyst-ratings" target="_blank" rel="noreferrer noopener">stock&#8217;s price target</a>.</li>
<li>Tenet Healthcare Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) stock lost 14.71% last week. Several healthcare stocks and hospital operators fell in possible sympathy with HCA Healthcare, which declined on Q3 earnings.</li>
<li>Universal Health Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) stock fell 14.33% last week after the company reported <a href="https://www.benzinga.com//node/41530333" target="_blank" rel="noreferrer noopener">Q3 financial results</a>.</li>
<li>HCA Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) stock fell 12.51% after reporting <a href="https://www.benzinga.com//node/41544243" target="_blank" rel="noreferrer noopener">worse-than-expected Q3 financial results</a>. The company expects Hurricane Helene&#8217;s impact to continue in 2025.</li>
<li>TopBuild Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLD#NYSE">BLD</a>) stock lost 11.48% last week as homebuilding stocks <a href="https://www.benzinga.com//node/41317881" target="_blank" rel="noreferrer noopener">took a beating</a> due to Hurricane Milton&#8217;s impact.</li>
<li>Carlisle Companies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSL#NYSE">CSL</a>) fell 11.45% last week on <a href="https://www.benzinga.com//node/41529849" target="_blank" rel="noreferrer noopener">worse-than-expected Q3 performance</a>.</li>
<li>Teradyne, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) stock declined 11.34% after it reported <a href="https://www.benzinga.com//node/41503363" target="_blank" rel="noreferrer noopener">third-quarter financial results</a>. Some analysts trimmed the <a href="https://www.benzinga.com/quote/ter/analyst-ratings" target="_blank" rel="noreferrer noopener">price target on the stock</a>.</li>
<li>Comfort Systems USA, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>) stock declined 11.27% after the company reported <a href="https://www.benzinga.com//node/41530044" target="_blank" rel="noreferrer noopener">worse-than-expected Q3 sales results</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/10/41560908/tesla-li-auto-and-microstrategy-are-among-top-10-large-cap-gainers-last-week-oct-21-oct-25-are-the">Tesla, Li Auto And MicroStrategy Are Among Top 10 Large Cap Gainers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio?</a></li>
</ul>

Large Cap

Movers

Genuine Parts Company, Universal Health Services, And TopBuild Are Among Top 10 Large Cap Losers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio?

TD Cowen analyst Charles Rhyee maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Buy and lowers the price target from $369 to $285.

TD Cowen Maintains Buy on Icon, Lowers Price Target to $285

Barclays analyst Luke Sergott maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Overweight and lowers the price target from $330 to $275.

Barclays Maintains Overweight on Icon, Lowers Price Target to $275

Goldman Sachs analyst Matthew Sykes maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Buy and lowers the price target from $370 to $280.

Goldman Sachs Maintains Buy on Icon, Lowers Price Target to $280

JP Morgan analyst Casey Woodring maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Overweight and lowers the price target from $375 to $280.

JP Morgan Maintains Overweight on Icon, Lowers Price Target to $280

Leerink Partners analyst Michael Cherny maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Outperform and lowers the price target from $376 to $270.

Leerink Partners Maintains Outperform on Icon, Lowers Price Target to $270

General

Icon shares are trading lower after Baird cut its price target on the company from $340 to $249. The stock may also be moving on continued weakness after reporting worse-than-expected Q3 financial results on Wednesday.

Baird analyst Eric Coldwell maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Neutral and lowers the price target from $340 to $249.

Baird Maintains Neutral on Icon, Lowers Price Target to $249

Investors with a lot of money to spend have taken a bearish stance on Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ICLR, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 16 uncommon options trades for Icon.
This isn't normal.
The overall sentiment of these big-money traders is split between 25% bullish and 56%, bearish.
Out of all of the special options we uncovered, 14 are puts, for a total amount of $801,840, and 2 are calls, for a total amount of $58,004.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $230.0 and $280.0 for Icon, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Icon stands at 129.33, with a total volume reaching 1,494.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Icon, situated within the strike price corridor from $230.0 to $280.0, throughout the last 30 days.
<h3>Icon 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729781137_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICLR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$45.0</td>
<td>$43.0</td>
<td>$45.0</td>
<td>$280.00</td>
<td>$166.5K</td>
<td style="text-align: right;">387</td>
<td style="text-align: right;">84</td>
</tr>
<tr>
<td>ICLR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$45.0</td>
<td>$43.8</td>
<td>$45.0</td>
<td>$280.00</td>
<td>$72.0K</td>
<td style="text-align: right;">387</td>
<td style="text-align: right;">34</td>
</tr>
<tr>
<td>ICLR</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$48.0</td>
<td>$45.6</td>
<td>$46.6</td>
<td>$280.00</td>
<td>$55.9K</td>
<td style="text-align: right;">387</td>
<td style="text-align: right;">187</td>
</tr>
<tr>
<td>ICLR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$47.4</td>
<td>$45.4</td>
<td>$46.1</td>
<td>$280.00</td>
<td>$55.3K</td>
<td style="text-align: right;">387</td>
<td style="text-align: right;">177</td>
</tr>
<tr>
<td>ICLR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$46.0</td>
<td>$44.8</td>
<td>$46.0</td>
<td>$280.00</td>
<td>$55.2K</td>
<td style="text-align: right;">387</td>
<td style="text-align: right;">126</td>
</tr>
</tbody>
</table>

<h3>About Icon</h3>
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
Following our analysis of the options activities associated with Icon, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Icon</h3>
<ul>
<li>With a volume of 2,053,491, the price of ICLR is down -16.9% at $233.31. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 118 days.</li>
</ul>
<h3>What Analysts Are Saying About Icon</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $338.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Redburn Atlantic lowers its rating to Neutral with a new price target of $311. 
&#x2A; Reflecting concerns, an analyst from Baird lowers its rating to Neutral with a new price target of $340. 
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Buy rating for Icon, targeting a price of $363. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Icon with a target price of $330. 
&#x2A; An analyst from Evercore ISI Group persists with their Outperform rating on Icon, maintaining a target price of $350. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Icon, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

Spotlight on Icon: Analyzing the Surge in Options Activity

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 150 points on Thursday.
Shares of International Business Machines Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) fell sharply in today's pre-market trading session following a <a href="https://www.benzinga.com/news/earnings/24/10/41502267/ibm-q3-earnings-software-revenue-jumps-10-on-great-momentum-in-ai-but-consulting-revenue-comes-in-f">third-quarter revenue miss</a>.
IBM reported third-quarter revenue of $14.968 billion, missing the consensus estimate of $15.07 billion, according to Benzinga Pro.
IBM shares tumbled 5% to $221.28 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>ICON Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) declined 16.3% to $235.13 in pre-market trading following worse-than-expected third-quarter financial results.</li>
<li>Garrett Motion Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTX#NASDAQ">GTX</a>) shares declined 12.6% to $6.97 in pre-market trading following weak quarterly sales.</li>
<li>Beyond, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NASDAQ">BYON</a>) shares dipped 12% to $8.38 in pre-market trading after the company reported worse-than-expected third-quarter adjusted EPS and sales.</li>
<li>Carrier Global Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) shares declined 9.9% to $72.00 in pre-market trading following worse-than-expected third-quarter revenues.</li>
<li>Spirit Airlines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVE#NASDAQ">SAVE</a>) shares fell 5.2% to $2.92 in pre-market trading after jumping 46% on Wednesday.</li>
<li>enGene Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) shares fell 4.1% to $8.96 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41508724/tesla-dow-and-3-stocks-to-watch-heading-into-thursday">Tesla, Dow And 3 Stocks To Watch Heading Into Thursday</a></li>
</ul>

Pre-Market Outlook

BYON

CARR

ENGN

SAVE

IBM Posts Weak Sales, Joins Garrett Motion, Beyond And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/603e4f87b3e2040001080043/tessa-romero">JP Morgan analyst Tessa Romero </a>downgraded the rating for Seres Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) from Neutral to Underweight. Seres Therapeutics shares closed at $0.7570 on Wednesday. <a href="https://www.benzinga.com/quote/MCRB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Jeffrey Zekauskas downgraded Avery Dennison Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>) from Overweight to Neutral and lowered the price target from $230 to $210. Avery Dennison shares closed at $207.65 on Wednesday. <a href="https://www.benzinga.com/quote/AVY/analyst-ratings">See how other analysts view this stock.</a></li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58933b2043eaaa0001698f4c/eric-coldwell">Baird analyst Eric Coldwell</a> downgraded the rating for ICON Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) from Outperform to Neutral and announced a $340 price target. Icon shares closed at $280.76 on Wednesday. <a href="https://www.benzinga.com/quote/ICLR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst Andrew Wittmann downgraded WillScot Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSC#NASDAQ">WSC</a>) from Outperform to Neutral and maintained the price target of $42. WillScot shares closed at $37.83 on Wednesday. <a href="https://www.benzinga.com/quote/WSC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Brandon Nispel downgraded the rating for Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) from Overweight to Sector Weight. Verizon shares closed at $42.86 on Wednesday. <a href="https://www.benzinga.com/quote/VZ/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying VZ stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="541" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24074850/image-233-1024x541.png" alt="" class="wp-image-611788" style="width:577px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24074850/image-233-1024x541.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24074850/image-233-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24074850/image-233-768x406.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24074850/image-233.png 1262w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41512422/top-3-tech-stocks-youll-regret-missing-in-q4">Top 3 Tech Stocks You&#8217;ll Regret Missing In Q4</a></li>
</ul>

Initiation

MCRB

This Verizon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

ICON shares are trading lower following worse-than-expected Q3 financial results. Also, Baird downgraded the stock from Outperform to Neutral and announced a $340 price target.

Baird analyst Eric Coldwell downgrades Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) from Outperform to Neutral and announces $340 price target.

Downgrades

Baird Downgrades Icon to Neutral, Announces $340 Price Target

Shares of Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rose sharply in today's pre-market trading after the company reported stronger-than-expected <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41509528/tesla-bull-gary-black-praises-ev-giants-clean-beat-in-q3-as-auto-margins-blow-past-">earnings for its third quarter</a>.
The automaker reported third-quarter earnings per share of 72 cents, beating a Street consensus estimate of 58 cents per share.
Tesla shares jumped 10.8% to $236.82 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>CCSC Technology International Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCTG#NASDAQ">CCTG</a>) rose 122% to $3.8800 in pre-market trading after gaining around 4% on Wednesday.</li>
<li>Mobile-health Network Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) gained 46.1% to $0.7449 in pre-market trading as the company posted FY24 results.</li>
<li>Qualigen Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLGN#NASDAQ">QLGN</a>) shares rose 37.4% to $0.2390 in pre-market trading.</li>
<li>CNS Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares surged 36.2% to $0.1920 in pre-market trading after declining around 10% on Wednesday. CNS Pharmaceuticals announced the pricing of $3 million registered direct offering of common stock priced at-the-market under Nasdaq rules.</li>
<li>Twin Vee Powercats Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEE#NASDAQ">VEEE</a>) rose 35.9% to $0.5874 in pre-market trading after gaining 16% on Wednesday.</li>
<li>DBV Technologies S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) shares jumped 21% to $0.8226 in pre-market trading. HC Wainwright &amp; Co. analyst Andrew Fein maintained DBV Technologies with a Buy rating and raised the price target from $5 to $7.</li>
<li>Seadrill Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDRL#NYSE">SDRL</a>) shares rose 13.1% to $39.78 in pre-market trading. Seadrill will report its third quarter results on Tuesday, Nov. 12 after the closing bell.</li>
<li>Inhibikase Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) climbed 11.1% to $2.70 in pre-market trading after jumping 15% on Wednesday.</li>
<li>Garrett Motion Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTX#NASDAQ">GTX</a>) gained 8.3% to $8.65 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>SaverOne 2014 Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) shares dipped 25.9% to $0.1079 in pre-market trading after surging 12% on Wednesday.</li>
<li>Gold Resource Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GORO#NYSE">GORO</a>) shares fell 25.8% to $0.3670 in pre-market trading after the company reported preliminary third-quarter and year-to-date results.</li>
<li>Osisko Development Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ODV#NYSE">ODV</a>) fell 18.6% to $2.05 in today's pre-market trading. Osisko Development announced a $50 million marketed private placement of 27,778,000 unit at $1.80/unit.</li>
<li>Zapata Computing Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZPTA#NASDAQ">ZPTA</a>) fell 17.2% to $0.0750 in pre-market trading after jumping 43% on Wednesday.</li>
<li>KWESST Micro Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KWE#NASDAQ">KWE</a>) fell 16.3% to $2.09 in pre-market trading after jumping 112% on Wednesday.</li>
<li>Orangekloud Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKT#NASDAQ">ORKT</a>) shares fell 15.1% to $6.46 in pre-market trading.</li>
<li>ICON Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) declined 16.3% to $235.13 in pre-market trading following worse-than-expected third-quarter financial results.</li>
<li>La Rosa Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRHC#NASDAQ">LRHC</a>) shares declined 15.9% to $0.9501 in pre-market trading after gaining over 130% on Wednesday. La Rosa Holdings reported preliminary 9-month revenue growth of 120% year over year.</li>
<li>Carrier Global Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) shares declined 9.9% to $72.00 in pre-market trading following worse-than-expected third-quarter revenues.</li>
<li>International Business Machines Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) shares fell 5% to $221.28 following a third-quarter revenue miss.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41508985/dow-records-worst-session-in-over-a-month-apple-nvidia-drag-nasdaq-down-fear-index-remains-in-greed">Dow Records Worst Session In Over A Month, Apple, Nvidia Drag Nasdaq Down: Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

CCTG

CNSP

DBVT

GORO

LRHC

MNDR

ORKT

Qualigen Therapeutics, Inc. - Common Stock

QLGN

SDRL

SVRE

TSLA

VEEE

ZPTA

Why Tesla Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket

ICON shares are trading lower following worse-than-expected Q3 financial results.

Guidance

ICON Sees FY24 Adj. EPS $13.90-$14.10, Revenue $8.26B-$8.30B

Earnings

Earnings Misses

Icon Q3 2024 GAAP EPS $2.36 Misses $2.58 Estimate, Sales $2.03B Miss $2.134B Estimate

Bank of America Securities analyst Michael Ryskin maintained a Buy rating on Icon (ICLR – Research Report) today. The company's shares opened today...

Icon (ICLR) Receives a Buy from Bank of America Securities

In a report released yesterday, Michael Cherny from Leerink Partners maintained a Buy rating on Icon (ICLR – Research Report), with a price target ...

Icon's Strategic Positioning for Long-term Growth Amid Current Challenges

Mizuho Securities analyst Ann Hynes has maintained their bullish stance on ICLR stock, giving a Buy rating today. Ann Hynes has given her Buy ratin...

Buy Rating for Icon (ICLR) Despite Q3:24 Challenges, Driven by Strategic Partnerships and Solid Fundamentals

ICON leads a selloff among CROs after guidance cut; Baird downgrades

Baird lowered the firm's price target on Icon (ICLR) to $249 from $340 and keeps a Neutral rating on the shares. The firm updated its model followi...

Icon price target lowered to $249 from $340 at Baird

TD Cowen analyst Charles Rhyee lowered the firm's price target on Icon (ICLR) to $285 from $369 and keeps a Buy rating on the shares. The firm view...

Icon price target lowered to $285 from $369 at TD Cowen

Icon (ICLR) has released an update. Icon plc's subsidiaries are providing guarantees for its Senior Secured Notes, which are due in 2027, 2029, and...

Icon plc Strengthens Investor Confidence with Secured Notes

ICON perks up after $250M share buyback

J.P. Morgan analyst Casey Woodring maintained a Buy rating on Icon (ICLR – Research Report) yesterday and set a price target of $280.00. The compan...

J.P. Morgan Keeps Their Buy Rating on Icon (ICLR)

Truist analyst Jailendra Singh lowered the firm's price target on Icon (ICLR) to $295 from $363 and keeps a Buy rating on the shares. With the Q4 a...

Comments

Icon

Vendite allo scoperto

Icon (NASDAQ:ICLR) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO